Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. (Q54594739)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21516080

Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. (English)

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21516080

1 reference

based on heuristic

inferred from title

immunohistochemistry

1 reference

based on heuristic

inferred from title

object named as

Rupert Langer

1

0 references

6

object named as

Helmut Friess

1 reference

Europe PubMed Central

1 June 2018

author name string

Sandra Rauser

2

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21516080

Marcus Feith

3

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21516080

Jörg M Nährig

4

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21516080

Annette Feuchtinger

5

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21516080

Heinz Höfler

7

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21516080

Axel Walch

8

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21516080

publication date

22 April 2011

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21516080

Modern Pathology

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21516080

24

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21516080

7

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21516080

908-916

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21516080

https://scigraph.springernature.com/pub.10.1038/modpathol.2011.52

0 references

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

HER-2 amplification is highly homogenous in gastric cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of A

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH).

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Evaluation of c-erbB-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett's adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Emerging drugs for esophageal cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

21 January 2018

c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

7 January 2021

based on heuristic

inferred from DOI database lookup

Significance of HER2 Low-Level Copy Gain in Barrett's Cancer: Implications for Fluorescence In situ Hybridization Testing in Tissues

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

7 January 2021

based on heuristic

inferred from DOI database lookup

Close association between HER-2 amplification and overexpression in human tumors of non-breast origin

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

7 January 2021

based on heuristic

inferred from DOI database lookup

Intratumoral genetic heterogeneity in Barrett adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.52

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/MODPATHOL.2011.52

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21516080

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21516080

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54594739&oldid=1456904570"